Dextrorphan

From Wikipedia, the free encyclopedia

Dextrorphan (DXO) is a pharmacologically active metabolite of dextromethorphan (DXM).

Dextrorphan
Systematic (IUPAC) name
17-methyl-9a,13a,14a-morphinan-3-ol
Identifiers
CAS number 125-73-5
ATC code  ?
PubChem 5360697
Chemical data
Formula C17H23NO 
Mol. mass 257.371 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Schedule I(US)

Routes  ?

Contents

[edit] Chemistry

It is the result of O-demethylation of the prodrug by several enzymatic systems, although it is chiefly a product of the Cytochrome P450 IID6 (CYP2D6) pathway.

[edit] Pharmacology

Dextrorphan is structurally similar to dextromethorphan, and has an affinity for the same receptors in the central nervous system, although with a slight difference in selectivity. While dextromethorphan is a weak non-competitive NMDA receptor antagonist, dextrorphan is a more potent antagonist[1].

It should be noted, however, that due to its potency as an NMDA receptor antagonist, as well as the fact that it is produced as a by-product of DXM metabolization in the body, DXO is thought to be largely responsible for the psychological side-effects that occur at high doses of DXM. These side-effects can include alteration of consciousness, or "cognitive dissociation", which are characteristic of NMDA blockade and which have afforded DXM its potential for use as a recreational drug.

[edit] See also

[edit] External links

Dextrorphan Legality

Languages